相关实验视频
Updated: May 23, 2025
08:36
In Vitro Assay to Study Tumor-macrophage Interaction
Published on: August 1, 2019
7.5K
帕克利塔塞尔,干扰素和功能重编程与瘤相关的巨细胞在优化的化疗免疫疗法中
Pawel Kalinski1, Kathleen M Kokolus2, Shipra Gandhi3
1Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA pawel.kalinski@roswellpark.org.
Journal for immunotherapy of cancer
|May 19, 2025
概括
化疗通过激活托尔类受体4 (TLR4) 信号来增强感冒瘤中的免疫检查点抑制 (ICI). 这种机制涉及巨细胞重编程,改善了诸如三阴性乳腺癌 (TNBC) 等癌症的反应.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫检查点抑制 (ICI) 针对编程细胞死亡蛋白-1 (PD1) 在许多固体瘤中是有效的,但不是缺乏T细胞透的"冷"瘤.
- 转移性三阴性乳腺癌 (TNBC) 对PD-1阻断的反应有限 (5-20%),尽管一些患者受益于化疗诱导的PD1敏感化.
- 化疗对PD1敏感的作用背后的机制及其在一小部分患者中的有限疗效仍然不清楚.
研究的目的:
- 阐明化疗使"冷"瘤对免疫检查点抑制 (ICI) 敏感的机制.
- 调查帕克利塔塞尔,托尔类受体4 (TLR4) 信号传递和干扰素途径在调解化疗免疫疗法的疗效方面的作用.
- 确定增强转移性三阴性乳腺癌 (TNBC) 和其他对分类素敏感癌症的化疗免疫疗法的策略.
主要方法:
- 对帕克利塔塞尔驱动的托尔类受体4 (TLR4) 信号通路的分析.
- 对瘤相关巨细胞 (TAMs) 中的1型和2型干扰素通路激活的研究.
- 在瘤微环境 (TME) 中评估M2到M1巨细胞过渡和瘤抗原交叉呈现.
主要成果:
- 帕克利塔塞尔治疗激活TLR4信号,导致TAMs中的1型和2型干扰素通路激活.
- 这种激活促进了局部M2到M1的巨细胞过渡,增强了瘤抗原交叉呈现.
- 激活TLR4的MyD88-NFκB通路在调解这些化疗免疫疗法的效果方面发挥着至关重要的作用.
结论:
- 帕克利塔塞尔诱导的TLR4信号传递和随后的干扰素在巨细胞中的激活是使"冷"瘤对ICI敏感的关键机制.
- 这一途径促进增强瘤抗原呈现和T细胞激活,改善抗瘤免疫力.
- 针对TLR4-MyD88-NFκB轴提供了一个有希望的策略,以提高TNBC和其他对分类素敏感的恶性瘤的化疗免疫疗法的疗效.
更多相关视频
相关概念视频
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K